San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Retrospective study of patients with HR+/HER2− metastatic breast cancer with bone-only metastases and pre-clinical data finds CDK4/6 inhibitors not as effective as in patients with metastases to other body sites. Read More ›

The development of action plans by providers and use of educational sessions found to improve patient compliance with oral oncolytics for those with HR+/HER2− breast cancer. Read More ›

Real-world analysis finds a preference shift from palbociclib to ribociclib and no significant differences in time to next treatment or time to treatment discontinuation for patients with HR+/HER-metastatic breast cancer. Read More ›

Study finds that patients with ER+/HER2− metastatic breast cancer who have prior CDK4/6 inhibitor treatment have a greater PFS when treated with elacestrant compared to standard of care. Read More ›

Oncology nurse navigators who work with younger patients with breast cancer and patients with metastatic breast cancer report barriers to services, information, and referrals. Read More ›

The phase 3 HER2CLIMB-02 trial demonstrated significant prolongation of progression-free survival with tucatinib plus ado-trastuzumab emtansine combination therapy in patients with previously treated HER2+ metastatic breast cancer (MBC). Read More ›

This correlative study identified significant differences in the expression of estrogen receptor between tumor tissue and circulating tumor cell analyses in metastatic breast cancer (MBC). Read More ›

In a prospective HER2+ metastatic breast cancer (MBC) cohort, one-third of patients achieved exceptional response to first-line HER2-targeted therapy, who presented more frequently with de novo disease and HER2 immunohistochemistry 3+ tumors. Read More ›

Updated overall survival analysis data from a retrospective chart review showed promising efficacy of T-DXd therapy in patients with HER2+ metastatic breast cancer (MBC) with long-term and heavily pretreated brain metastases and/or leptomeningeal carcinomatosis. Read More ›

The phase 3, randomized, double-blind HER2CLIMB-05 study (NCT05132582) is evaluating the addition of tucatinib to trastuzumab plus pertuzumab as maintenance therapy in patients with HER2+ metastatic breast cancer (MBC). Read More ›

Page 1 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications